The global insulin delivery pens market size is predicted to increase from USD 25,578 million in 2025 and is anticipated to ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

The U.S. Food and Drug Administration (FDA) and drug manufacturer Novo Nordisk are warning consumers about “counterfeit” Ozempic found outside the authorized drug supply chain. The contents of the ...

Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out ...

Indian diabetic population on Human Mixtard concerned on changes in insulin therapy: Nandita Vijayasimha, Bengaluru Thursday, April 24, 2025, 08:00 Hrs [IST] India’s diabetic po ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Novo Nordisk clarifies Human Mixtard penfill to be replaced with injectables: Our Bureau, Bengaluru Wednesday, April 23, 2025, 13:30 Hrs [IST] Denmark-based global pharma major, N ...

Thirty-seven-year-old Nupur Lalvani, who has been living with Type 1 diabetes since the age of eight, was dependent on ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...

Report Ocean, a leading strategic consulting and market research firm, in its recent study, estimated the Asia Pacific Lancet and Pen Needles Market size at USD 1,416.30 million in 2023. During the ...

Novo Nordisk’s insulin brand Mixtard will continue to be available in vials, the Danish healthcare company clarified, even as ...